Pfizer and Merck have announced that avelumab alone or in combination with pegylated liposomal doxorubicin (PLD) has failed to improve overall survival (OS) or progression-free survival (PFS) rate in phase III Javelin Ovarian 200 trial.
AstraZeneca’s Imfinzi (durvalumab) monotherapy and the combination of Imfinzi with remelimumab have failed to improve overall survival (OS) rate in phase III Mystic lung cancer trial.
Seattle Genetics has dosed the d first patient in a phase 1 clinical trial evaluating the safety and tolerability of SEA-BCMA for patients with relapsed or refractory multiple myeloma (MM).
Merck has announced that its anti-PD-1 therapy Keytruda (pembrolizumab) significantly improved overall survival (OS) rate in the phase 3 Keynote-181 esophageal cancer trial.
AbbVie’s Mavyret (glecaprevir/pibrentasvir) has showed high virologic cure rates in treatment-naïve patients with compensated cirrhosis in the phase 3b Expedition-8 study.
Gilead Sciences announced that its GS-9674 has showed significant improvements in liver biochemistry and markers of cholestasis in patients with primary sclerosing cholangitis (PSC) in a phase 2 trial.
Clinical stage biotechnology firm Visterra has commenced a phase 1 clinical study of VIS649 in healthy volunteers.
UK-based 4D pharma has commenced patient enrollment for a phase 2 clinical trial to evaluate its single-strain live biotherapeutic candidate Blautix to treat Irritable Bowel Syndrome (IBS).
Glenmark Pharmaceuticals has announced plans to launch a phase 1 trial in solid tumors for its CD38xCD3 bispecific antibody GBR 1342.
Genkyotex’s NOX1/4 inhibitor GKT831 has succeeded in a phase 2 trial in primary biliary cholangitis (PBC), a type of liver disease, by meeting both primary and secondary interim efficacy endpoints.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.